Kornimate/medical-research-clean huggingface dataset:
treatment for non-suicidal self-injury in young adults

Conditions: Non-suicidal Self-injury

Summary: the purpose of this study is to investigate an intervention specifically for non-suicidal self-injury (nssi) in young adults. the goal of this 9-session outpatient intervention is to reduce the frequency and severity of nssi. during phase i, 12 patients will be treated in an open pilot trial. during phase ii, 60 patients will be treated in a randomized controlled pilot study in order to determine the feasibility and acceptability of the intervention and to investigate change in nssi frequency and severity over time.

non-suicidal self-injury (nssi), deliberate harm to the body without suicidal intent, is highly prevalent in young adults, with 1 in 10 college students engaging in over 100 episodes in their lifetimes. consequences of nssi are severe, including physical injury ranging in medical severity, distress from shame associated with the behavior, social isolation, psychological symptoms, and increased risk and lethality of nssi over time. despite the prevalence and significant consequences of nssi, no empirically supported treatments specific to nssi exist. the purpose of this study is to develop, implement, and evaluate an intervention specifically for nssi in young adults, the treatment for self-injurious behaviors (t-sib). this time-limited intervention will integrate theoretically-based strategies whose utility has been identified through empirical research with the goal of reducing frequency and severity of nssi. the research plan consists of 2 phases. during phase 1, 12 patients will be treated in an open pilot trial. during phase 2, 60 patients will be treated in a randomized controlled pilot study to determine the feasibility and acceptability of t-sib, investigate change in nssi frequency and severity between t-sib and treatment as usual (tau) through a 3-month follow up period, and evaluate the research design of the randomized controlled pilot study to inform both the utility and design of a larger randomized clinical trial.

Eligibility criteria:
inclusion criteria: * ages 18-29 * nssi within the past month or history of nssi and urge to self-injure within the past month exclusion criteria: * psychotic symptoms * severe suicidal ideation

Keywords: self-injury non-suicidal self-injury deliberate self-harm self-mutilation
driveline silicone skin interface registry

Conditions: Driveline Heart-assisted Device Related Infection

Summary: the purpose of this observational registry is to determine the freedom from driveline (dl) infection events in subjects implanted with a heartmate ii lvad in whom only the silicone portion of the dl is externalized resulting in a silicone skin interface (ssi)


Eligibility criteria:
inclusion criteria: * subject has signed the intermacs informed consent form * subject has signed the ssi registry informed consent form * subject age ≥ 18 years * subject implanted with a heartmate ii lvad * subject in whom the full length of the velour portion of the percutaneous lead is fully kept under the skin resulting in a silicone skin interface at the skin exit site * in the prospective study cohort, subject is planned to be supported with the heartmate ii lvad for at least 12 months * in the retrospective study cohort, at the time of enrollment, subject has been supported with a heartmate ii for at least 10 months exclusion criteria: * in the retrospective study cohort, subject is ongoing with long-term right heart mechanical circulatory support (rvad) * in the retrospective study cohort, subject had a post-implant sternal re-entry (for bleeding, etc.) or delayed sternal closure * in the retrospective study cohort, subject is participating in any other clinical investigation related to driveline (dl) exit site that could confound the study results * in the prospective study cohort, subject is participating in any other clinical investigation related to driveline (dl) exit site that could confound the study results

Keywords: heartmate ii heart-assist device left ventricular assist device driveline infection lvad hmii lvas driveline silicone portion thoratec corporation
clinical trials to assess safety and efficacy of dwrx2003 combination with remdesivir in moderate to severe covid-19 patients.

Conditions: COVID-19

Summary: safety and efficacy of dwrx2003 combination with remdesivir in moderate to severe covid-19 patients will be confirmed.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years at time of signing the informed consent form (icf). * sars-cov-2 infection documented by rt-pcr within 7 days prior to randomization. * hospitalized patients who meet the criteria of moderate or severe covid-19. * patients who are not pregnant, based on urine pregnancy test during screening, and randomization. * female patients of childbearing potential practice effective contraception during the study and be willing and able to continue contraception for 60 days after their dose of study treatment. * male patient and/or female patient's partner agree to use condoms or should have undergone vasectomy or spermicide in addition to female contraception for additional protection against conception for 60 days after their dose of study treatment. * patients who are anticipated to available for the entire study period and is capable of understanding and communicating with the investigators and clinical study facility staff. * patients who agree to give written informed consent and are willing to participate in the study. exclusion criteria: * patients with bmi ≥30 and/or body weight \< 40kg * patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. * patients who cannot be administered intramuscularly to bilateral ventro-gluteal area. * patients with uncontrolled respiratory disease other than covid-19 pneumonia (i.e. copd, asthma, cystic fibrosis, etc.) * patients who have active malignancy, history of active malignancy or chemotherapy within 1 year from the screening.
study to assess effectiveness of giving combination of standard chemotherapy drugs versus combination of standard chemotherapy and new drug ixabepilone when given before surgical removal of early stage breast cancer

Conditions: Breast Cancer

Summary: the study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (ac) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. in addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.


Eligibility criteria:
inclusion criteria * histologically confirmed primary invasive adenocarcinoma of the breast , t2-3, n0-3, m0, with tumor size of ≥ 2 cm * all patients with early stage breast adenocarcinoma may enroll irrespective of receptor status * no prior treatment for breast cancer excluding therapy for dcis * karnofsky performance status of 80 - 100 * left ventricular ejection fraction (lvef) ≥ 50% by echocardiogram or multiple gated acquisition (muga) * adequate hematologic, hepatic and renal function exclusion criteria * women of child-bearing potential (wocbp) unwilling or unable to use an acceptable method to avoid pregnancy during and up to 8 weeks after the last dose of the investigational drug * women who are pregnant or breastfeeding * inflammatory or metastatic breast cancer * unfit for breast and/or axillary surgery * evidence of baseline sensory or motor neuropathy * significant history of cardiovascular disease, serious intercurrent illness or infections including known human immu immunodeficiency virus (hiv) infection * history of prior anthracycline therapy allergies to any study medication or cremophor® el

Keywords: early breast cancer
combination of vitamin c and n-acetylcysteine to improve functional outcome after rotator cuff repair

Conditions: Rotator Cuff Tears

Summary: the goal of this clinical trial is to learn if vitamin c and n-acetylcysteine work to improve shoulder functional score after rotator cuff repair. it will also learn about the safety of vitamin c and n-acetylcysteine. the main questions it aims to answer are: do vitamin c and n-acetylcysteine improve the shoulder functional score of participants? do vitamin c and n-acetylcysteine improve healing of rotator tendon? researchers will compare vitamin c and n-acetylcysteine to a placebo (a look-alike substance that contains no drug) to see if vitamin c and n-acetylcysteine works to improve shoulder functional score after rotator cuff repair. participants will: take vitamin c and n-acetylcysteine or a placebo every day for 45 days. visit the opd three times at 2 week, 6 month and 12 month after surgery for checkups and tests.


Eligibility criteria:
inclusion criteria: * all patient who undergone arthroscopic primary rotator cuff complete repair. * clinical history and symptom consistent with rotator cuff tear. * mri confirmation of rotator cuff tear. exclusion criteria: * non-reparable or partial rotator cuff repair. * high grade fatty degeneration of the rotator cuff (goutallier iii, iv) * at least one torn tendon with retraction to the glenoid (stage 3 of patte classification) * rotator cuff retear. * isolated subscapularis tear. * patient who loss follow up. * patent who cannot respond questionnaire. * patient who allergy to vitamin c or n-acetylcysteine.

Keywords: ascorbic acid acetylcysteine rotator cuff repair
expansion of scg/gcg-based cad sceering: inclusion of healthy controls and ccta patients

Conditions: Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))

Summary: this study evaluates a new, non-invasive method for screening coronary artery disease (cad) using seismocardiography (scg) and gyrocardiography (gcg). these techniques measure chest vibrations caused by heart activity using highly sensitive sensors. participants include patients with known or suspected cad, as well as healthy individuals and those undergoing coronary computed tomography angiography (ccta). the goal is to determine whether scg/gcg testing can accurately differentiate between individuals with significant and non-significant coronary artery stenosis. scg/gcg testing will be conducted before standard diagnostic procedures, including coronary artery calcium computed tomography (cac-ct) and ccta. the results will be analyzed to compare the performance of this novel method with existing imaging techniques. this research aims to provide a non-invasive, cost-effective alternative for screening cad.


Eligibility criteria:
inclusion criteria: * age 40 years or older. * electively scheduled for cac-ct and have an indication for ccta * suspected coronary artery disease (cad) based on the presence of: * at least two cardiovascular risk factors (e.g., hypertension, smoking, diabetes, dyslipidemia, obesity). * cad-related symptoms (e.g., chest pain, dyspnea on exertion). * suspected congenital coronary abnormalities. * ability to provide informed consent. exclusion criteria: * severe cardiac arrhythmias that may interfere with scg/gcg recordings. * decompensated heart failure or severe valvular heart disease. * other clinically significant concomitant diseases that may impact study participation. * history of heart surgery (e.g., recent cabg, valve replacement) that alters chest wall dynamics. * contraindications for undergoing cac-ct or ccta (e.g., severe renal insufficiency preventing contrast use). * inability to remain still in supine or upright sitting positions for testing. * inability to provide informed consent due to cognitive or neurological conditions.

Keywords: coronary artery disease seismocardiography cardioclin
efficacy and safety of candesartan associated with chlorthalidone in essential arterial hypertension control

Conditions: Essential Arterial Hypertension

Summary: the purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.


Eligibility criteria:
inclusion criteria: * signed consent of the patient; * participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the brazilian society of cardiology (2010), who have never been treated and have indication for drug combination treatment. obs: the diagnosis may be established by previous evaluation of two blood pressure measures ≥ 140/90 mmhg, with two months difference between measurements exclusion criteria: * patients with any clinically significant disease that in the investigator is opinion can not participate in the study; * secondary hypertension diagnosis or blood pressure above 190x100 mmhg in the screening/randomization visit; * morbid obesity or immunocompromised patients; * participants with greater than 10 mmhg difference in the measurements of systolic or diastolic blood pressure between the two arms; * participants who do not have the two upper limbs; * participants with important electrocardiographic changes; * creatinine clearance - less than 60 ml /min; * history of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months; * microalbuminuria in urine sample greater than 30 mg/g; * patients with history of hypersensitivity to any of the formula compounds; * pregnancy or risk of pregnancy and lactating patients; * participation in clinical trial in the year prior to this study.
optimal anesthetic for corticosteroid injections for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: to evaluate pain relief from corticosteroid injection with and without anesthetic as well as with variable volume of anesthetic. pain relief will be measured using the vas pain score at the time of the injection as well as several time points following the injection to capture pain relief longevity. the investigators intend to evaluate how well the patients tolerate corticosteroid mixtures without anesthetic as well as with different volumes of anesthetic. primary measure will be the time from procedure when postoperative status is considered success (as measured by global perceived improvement score).

primary objective is to evaluate pain relief from corticosteroids, kenalog without anesthetic as well as with different volumes of anesthetic. the investigators will measure the vas pain score at the time of the injection as well as several time points following the injection. additionally, the investigators will evaluate how long the injection provided pain relief for the patient. the secondary intend is to evaluate how well the patients tolerate kenalog mixtures without anesthetic as well as with different volumes of anesthetic by using the vas pain scale. the investigators hypothesize that patient with lower volume of injection will experience less pain during the procedure and that there will be no statistically significant difference in pain level between the study groups during the study period.

Eligibility criteria:
inclusion criteria: 1. patients must be 18 years of age and be able to consent for themselves. 2. oa grade kellgren lawrence stage ii or iii. 3. diagnosis of primary osteoarthritis. exclusion criteria: 1. patients with other forms of arthritis such as inflammatory arthritis. 2. history of narcotic use for the past 6 months. 3. kellgren lawrence arthritis grade 1 or 4. 4. pregnant women and prisoners.

Keywords: knee injection knee osteoarthritis corticosteroid
recovery of tiva vs inhalation in pediatric anesthesia

Conditions: Best Technique for Pediatric Anesthesia

Summary: compare recovery profile from tiva and that of total inhalational anesthesia in ambulatory pediatric tonsillectomy and which strategy is more safe and less cost and more smooth in pediatric anesthesia.

complications in pediatric anesthesia can happen even in our modern hospitals with the most advanced equipment and skilled anesthesiologists. typical complications in pediatric anesthesia are respiratory problems , medication errors , difficulties with intravenous puncture , and pulmonal aspiration. in postoperative setting , nausea and vomiting , pain , emergence delirium can be mentioned as typical complications. the choice of anesthetic agent and techniques can influence the occurrence of these complications and thus delay in discharge.

Eligibility criteria:
inclusion criteria: * child between 4 to 10 years * without co morbidity * asa score 1 * mallampati score 1 and 2 exclusion criteria: * child below 4 years and above 10 years * child with co morbidity * asa score above 1 * mallampati score 3 and 4
collection of spot egms and intra-cardiac impedance for atrio-ventricular and inter-ventricular delays optimization

Conditions: Heart Failure

Summary: the purpose of the study is to collect data from the two implanted sensors simultaneously to the surface ecg and echocardiographic measurements of electromechanical parameters, in crt patients.

the saturn study is a prospective, interventional, open-label, non-randomized, single-arm, acute, multicenter feasibility study. the purpose of the study is to collect data from the two implanted sensors simultaneously to the surface ecg and echocardiographic measurements of electromechanical parameters. the data collected will be analysed in order to explore the relevance of timings and morphological features derived from those signals in comparison with timings determined on echocardiography and electrocardiograms (ecg) in various configurations of atrioventricular (av) and inter-ventricular (vv) delays. a maximum of 35 subjects, implanted with a crt-d device, will be enrolled, at approximately 6 sites in france. each patient will participate to this study only during an echocardiographic procedure, whose duration is estimated in approximately 1.5 hour.

Eligibility criteria:
inclusion criteria: * patient with class i or ii indication for implantation of a crt-d device according to current esc guidelines * patient newly implanted with a microport crm platinium crt-d sonr or platinium crt-d device within 2 months before the investigational procedure * patient in sinus rhythm with a preserved atrio-ventricular conduction, and pr interval=220 +/- 30 ms on surface ecg * patient has reviewed, signed and dated the study informed consent form exclusion criteria: * patient with permanent or persistent atrial fibrillation or atrial flutter * patient presenting with a permanent or frequent paroxysmal high degree atrio-ventricular block * device upgrade or replacement * minor patient (i.e. under 18 years of age), or patient under guardianship or kept in detention * patient unavailable for the scheduled investigational procedure, not able to understand the purpose of this study or refusing to cooperate
genetic analysis of thyrotoxic periodic paralysis

Conditions: Thyrotoxic Periodic Paralysis

Summary: thyrotoxic periodic paralysis (tpp) is characterized by episodes of reversible hypokalemia and weakness in thyrotoxic patients. it is commonly found in males of asian descent and is also seen in individuals having native american or hispanic ancestry. therefore genetic etiology has been hypothesized. this study, we aim to find the susceptibility genes that associate with tpp. both candidate genes approach and genome wide association study have been conducted.

this study is a genetic association study. it included 50 cases of tpp patients and 80 cases of male, hyperthyroid patients who didn't have hypokalemia as a well characterized controls. after informed consent were obtained, genomic dna from leukocyte were extracted. pooled dna were constructed and whole genome scan using 10k genechip microarray were genotyped on pooled genomic dna.

Eligibility criteria:
inclusion criteria: tpp * hyperthyroid patients from any causes * evidence of hypokalemia (k\<3.5 mg/dl)from intracellular shift (urine k\<15 mg/dl, ttkg\<2) * episodic paralysis exclusion criteria: * hypokalemia from gi or renal loss

Keywords: thyrotoxicosis genetic association study periodic paralysis whole genome scan
treatment of adults aged up to 60 years with de novo acute myeloblastic leukaemia,secondary aml, or raeb-t

Conditions: De Novo Akute Myeloid Leukemia (AML); Secondary Acute Myeloid Leukemia (AML); Refractory Anemia With Excess of Blasts in Transformation

Summary: this randomized phase ii/iii trial investigates the antileukemic activity and toxicity of the flag-ida regimen as a second induction course in patients with acute myeloid leukaemia and bad response to the first induction cycle and/or with a high risk karyotype and compares the antileukemic activity and toxicity of high dose cytarabine/daunorubicin vs. autologous peripheral blood stem cell transplantation as late consolidation therapy in standard risk patients.

assessment of the antileukemic activity and toxicity of the flag-ida regimen as a second induction course in patients with bad response to the first induction cycle and/or with a high risk karyotype. optimization of the late consolidation therapy in standard risk patients (sr) by a prospective randomized trial comparing a high-dose cytarabine/daunorubicin (hd-ara-c/dnr) based late consolidation therapy with an autologous peripheral blood stem cell transplantation (pbsct) assessment of the antileukemic activity of the different treatment elements by monitoring residual disease (mrd) after induction, early and late consolidation by real-time pcr assessment of the prognostic relevance of minimal residual disease by quantification of the residual leukemic burden in haematological remission by real-time pcr during follow-up

Eligibility criteria:
inclusion criteria: * diagnosis of de-novo aml, fab m 1, 2, 4 - 7 * diagnosis of secondary aml after chemo-/radiotherapy or mds * diagnosis of raeb-t * age between 16 and 60 years (including 60 years) * women after exclusion of pregnancy * written informed consent exclusion criteria: * patients with severe disease of the heart (e.g. cardial failure nyha iii/iv; history of myocardial infarction within the last 6 months;severe ventricular arrythmias (lown iii to iv) * patients with dlco \< 50% * patients with creatinine clearance \< 60 ml/min * patients with bilirubin \> 2mg% (34.2 mmol/l) * patients with severe complications of the leukaemia such as uncontrolled bleeding, pneumonia with hypoxia or shock * patients with a psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participating in this study * hiv positivity * patients with a t(15;17) translocation
the effect of body mass index (bmi) on inpatient stroke rehabilitation outcome: a prospective study from an east-asian cohort

Conditions: Weight Change, Body; Stroke

Summary: research has shown that rehabilitation at almost any body mass index (bmi) level leads to positive functional outcomes. some data demonstrating that gains are often more rapid at bmi above "normal". the aim of this study is to investigate the association between bmi and the functional progress of all patients admitted to tan tock seng tertiary rehabilitation center.


Eligibility criteria:
inclusion criteria: * clinical strokes (ischaemic or haemorrhagic) diagnosed by acute neurologists or neurosurgeons and confirmed on computerized tomography (ct) or magnetic resonance imaging (mri) brain imaging * aged 18 years and above * admitted directly from acute stroke units * able to provide informed consent by self or by next of kin in incompetence patient * must receive physical therapy (either physiotherapy, occupational therapy or speech therapy) at least 5 times a week with each session at least 30 minutes exclusion criteria: * rehabilitation was not the primary reason for the inpatient admission * failure to complete the rehabilitation program due to either an acute transfer off rehabilitation or a discharge against medical advice * incomplete or missing body mass index (bmi) or functional independence measure (fim) data * patients who were not of asian ethnicity

Keywords: body mass index stroke rehabilitation